Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers
Open Access
- 11 October 2021
- journal article
- Published by American Society of Hematology in The Hematologist
- Vol. 18 (6)
- https://doi.org/10.1182/hem.v18.6.202163
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 DosesJAMA, 2021
- Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignanciesPublished by Cold Spring Harbor Laboratory ,2021
- A correlate of protection for SARS-CoV-2 vaccines is urgently neededNature Medicine, 2021
- Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patientCancer Cell, 2021
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19The New England Journal of Medicine, 2021
- High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patientsNephrology Dialysis Transplantation, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- COVID-19 and Cancer: Current Challenges and PerspectivesCancer Cell, 2020